GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2004 | 09-2004 | 06-2004 | 03-2004 | 12-2003 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,698 | -1,839 | -1,786 | -593 | -791 |
| Depreciation Amortization | 827 | 593 | 398 | 186 | 177 |
| Accounts receivable | 22 | -119 | 53 | -40 | -63 |
| Accounts payable and accrued liabilities | -118 | -73 | 27 | -70 | 288 |
| Other Working Capital | 499 | 107 | 516 | -101 | 291 |
| Other Operating Activity | 426 | 239 | -33 | 135 | -131 |
| Operating Cash Flow | $-1,042 | $-1,092 | $-825 | $-483 | $-229 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -47 | -24 | -16 | -2 | -13 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 62 |
| Purchase Sale Intangibles | -262 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -262 | -240 | -150 | -85 | -147 |
| Investing Cash Flow | $-309 | $-264 | $-166 | $-87 | $-98 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,686 | 486 | 486 | 486 | N/A |
| Common Stock Issued | 4,006 | 80 | 50 | 24 | 247 |
| Other Financing Activity | 0 | 1,200 | 1,200 | 0 | 0 |
| Financing Cash Flow | $5,692 | $1,766 | $1,736 | $510 | $247 |
| Exchange Rate Effect | -26 | 4 | -2 | -4 | 28 |
| Beginning Cash Position | 372 | 372 | 372 | 372 | 424 |
| End Cash Position | 4,687 | 786 | 1,115 | 308 | 372 |
| Net Cash Flow | $4,315 | $414 | $743 | $-64 | $-52 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,042 | -1,092 | -825 | -483 | -229 |
| Capital Expenditure | -47 | -24 | -16 | -2 | -13 |
| Free Cash Flow | -1,089 | -1,116 | -841 | -485 | -242 |